Marlborough Alzheimer’s treatment firm announces new board
Courtesy | Cognoptix
Marlborough’s Cognoptix, a healthcare company developing a system for early detection of Alzheimer’s disease, has formed a new board of directors following a recent funding round.
The new board was formed under the leadership of Dr. Susanne Wilke, Cognoptix' new president and CEO. In addition to Wilke, the five-member board includes Dr. Lee Goldstein, Cognoptix co-founder and co-chair of the company's scientific advisory board; Gregg Stone and John Conley, both members of the Launchpad Venture Group in Newton, which led the Cognoptix Series R fundraising; and Lawrence Remmel, partner and chair of the banking and finance group at Pryor Cashman in New York City
"Cognoptix' Board of Directors will provide crucial leadership to guide the transformation of the company from its previous R&D focus, to achieving [U.S. Food & Drug Administration] approval and commercialization of its SAPPHIRE II system," Wilke said in a release.
The company is planning to pursue a clinical study of its system in 2021.
WBJ Web Partners
Most Recent
Most Recent
0 Comments